2024-10-25 16:34:04 ET
Chugai Pharmaceutical Co., Ltd. (CHGCF)
Q3 2024 Earnings Conference Call
October 25, 2024, 5:00 AM ET
Company Participants
Kae Miyata - Corporate Communications Department
Osamu Okuda - President and CEO
Tsukasa Kusano - Executive Vice President, Head, Project and Lifecycle Management Unit
Iwaaki Taniguchi - Chief Financial Officer
Junichi Takano - Head, Marketing and Sales Division
Conference Call Participants
Seiji Wakao - JPMorgan
Hidemaru Yamaguchi - Citigroup Securities
Shinichiro Muraoka - Morgan Stanley MUFG Securities
Tony Ren - Macquarie Capital
Hiroshi Wada - SMBC Nikko Securities
Kazuaki Hashiguchi - Daiwa Securities
Kasumi Haruta - UBS Securities
Presentation
Kae Miyata
Thank you for joining Chugai Pharmaceutical’s Earnings Call on the Financial Results for the Fiscal Year 2024 Third Quarter. I am Miyata from Corporate Communications Department. I would like to serve as your moderator today.
Today, we have an on-site presentation, as well as a Zoom webinar. And today’s agenda is in the document distributed. And today’s call is going to be held in Japanese, but through the Zoom webinar, you will be able to listen to the simultaneous interpretation in English. Please find the interpretation mark at the bottom of the screen and select the language of your choice.
We will take questions after the presentations. We plan to have 30 minutes for the question-and-answer session following the presentations. During the presentations, please allow us to mute your microphones. We thank you for your cooperation.
Now, Dr. Osamu Okuda is going to present the fiscal year 2024 third quarter overview.
Osamu Okuda
Okuda, the President. I would like to give you the third quarter of the financial year 2024. Please take a look at Page 5. Up to the third quarter, we have achieved increased revenue and profit. Revenue increased by 3.7% year-on-year. This is a turnaround from the slight decrease in the revenue in the second quarter. Operating profit increased by 25.3% year-on-year. So it has continued to increase year-on-year. And both are higher than our original forecast.
Domestic sales decreased significantly due to the completion of government supply of Ronapreve, which was recorded last year and NHI drug price revisions, as well as the impact of generics. Overseas sales and other revenue increased significantly, particularly due to exports of Hemlibra, the in-house product, to Roche and royalty income....
Read the full article on Seeking Alpha
For further details see:
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript
